Gruss E.
DOR BioPharma to Host Webcast to Discuss Implications of President Bush's $6 Billion Project Bioshield
LAKE FOREST, Ill., Jan 29, 2003 (BUSINESS WIRE) -- Visit www.dorbiopharma.com
Friday, January 31st at 12:00 Noon ET
DOR BioPharma Inc. (AMEX: DOR) ("DOR") announced today that it will host a
webcast on Friday, January 31st at 12:00 noon Eastern Time. DOR will discuss the
implications of President Bush's $6 billion Project Bioshield biodefense vaccine
stockpile initiative unveiled in his State of the Union address last evening as
it relates to DOR's biodefense vaccines and business.
Utilizing its proprietary Microvax(TM) mucosal vaccine delivery technology, DOR
is developing oral and intranasal synthetic (non-live) vaccines for bioterror
threats, such as, ricin and anthrax. Such vaccines have the ability to be
stockpiled and rapidly deployed to civilian populations for homeland security.
In addition to these benefits, DOR's vaccine candidates have the ability to
confer mucosal immunity, the body's first line of defense against bioterror
agents, while avoiding the safety concerns associated with the use of live
vaccine pathogens.
To attend the webcast, please visit DOR's website at www.dorbiopharma.com
several minutes prior to 12:00 noon Eastern Time on Friday to avoid missing the
beginning of the webcast. The webcast will include a question and answer session
following the audio-visual presentation. Participants interested in asking
questions should call the company at (847) 573-8990 in advance of the webcast to
make telephonic arrangements.
DOR BioPharma, Inc.
DOR BioPharma, Inc. is a specialty pharmaceutical company specializing in the
oral delivery of approved chemical entities and synthetic (non-live) mucosally
administered vaccines that may conveniently and rapidly confer mucosal immunity
(such as in the lungs) against potentially the entire spectrum of identified
bioterror threats, while completely avoiding the risks associated with vaccines
that contain live replication competent pathogens or genetic material. The
Company's lead product, orBec(R) (oral beclomethasone dipropionate), is
currently in a pivotal phase III clinical trial for the treatment of intestinal
graft-vs.-host disease and the Company is currently testing orBec's(R)
usefulness in treating a large percentage of persons diagnosed with irritable
bowel syndrome (IBS), a disease that affects approximately 35 million persons in
the U.S. alone. The Company's synthetic (non-live) mucosally administered
vaccine MicroVax(TM) technology is protected by worldwide issued patents under
license to the Company for various fields of use, including U.S. patents,
6,024,983; 5,942,252; 5,853,763; 5,820,883; 5,814,344; and 5,811,128 as well as
European patents EP 0 266 119 and EP 0 333 523 and other additional
corresponding international patents. For further information regarding DOR
BioPharma, please visit the company's website located at www.dorbiopharma.com.
This press release contains and the associated webcast will contain
forward-looking statements, within the meaning of Section 21E of the Securities
Exchange Act of 1934, that reflect DOR BioPharma's current expectations about
its future results, performance, prospects and opportunities, including its
product development and product pipeline. Where possible, DOR BioPharma has
tried to identify these forward-looking statements by using words such as
"anticipates," "believes" or similar expressions. These statements are subject
to a number of risks, uncertainties and other factors that could cause actual
events or results in future periods to differ materially from what is expressed
in, or implied by, these statements. DOR BioPharma cannot assure you that it
will be able to successfully develop or commercialize products based on its
technology, particularly in light of the significant uncertainty inherent in
developing mucosally administered vaccines against bioterror threats,
manufacturing and conducting preclinical and clinical trials of vaccines, and
obtaining regulatory approvals, that its technologies will prove to be safe and
effective, that its cash expenditures will not exceed projected levels, that it
will be able to obtain future financing or funds when needed, that, that product
development and commercialization efforts will not be reduced or discontinued
due to difficulties or delays in clinical trials or due to lack of progress or
positive results from research and development efforts, that it will be able to
successfully enter into profitable biodefense contracts with the U.S. Department
of Homeland Security, U.S. Department of Defense and other countries, patent,
register or protect its technology from challenge and products from competition
or maintain or expand its license agreements with its current licensors, or that
its business strategy will be successful. These and other factors are described
from time to time in filings with the Securities and Exchange Commission,
including, but not limited to, DOR BioPharma's most recent reports on Form
10-QSB and Form 10-KSB. DOR BioPharma assumes no obligation to update or revise
any forward-looking statements as a result of new information, future events,
changed circumstances or for any other reason.
CONTACT: DOR BioPharma Inc.
David M. Kent, 847/573-8990
dkent@dorbiopharma.com
or
Redington, Inc.
Thomas Redington, 203/222-7399
mgroen.bei.t-online.de/Er%f6ffnung%205%20KW.jpg" style="max-width:560px" > 
